Indication
Dazparda is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Loading your page…
Loading your page…
Diabetes Mellitus
Marketing Authorisation Holder: Gan & Lee Pharmaceuticals Europe GmbH
EMA Authorisation: 27/04/2026
INN: insulin aspart
AI Drug & Interaction Analysis
Free account required
Ask Osler about Dazparda: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.